These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://lorifzdy667461.activoblog.com/47516340/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide